The FDA-approved device tackles venous obstructions with a dual-stent design that includes hybrid and extend stents, according to a June 18 system news release shared with Becker’s. The study that led to its FDA approval enrolled 162 subjects across 30 centers, including Sanger. It found after 12 months, 90.2% of treated veins remained open and unobstructed and that the system had a success rate of 98.7%.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.